Trials / Recruiting
RecruitingNCT07203287
Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 490 (estimated)
- Sponsor
- The University of Texas Medical Branch, Galveston · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
Detailed description
Participants will be randomized into one of the two groups (Group 1-Given rocuronium and sugammadex as part of one of the standard regimens of neuromuscular blockade and reversal or Group 2-Given cisatracurium and neostigmine as part of one of the standard regimens of neuromuscular blockade and reversal). Both of which are current standard of care practices. Appropriate reversal will be performed and documented, and the patient will go to the recovery room or intensive care unit as planned preoperatively. The patients will be assessed postoperatively for up to 7 days for any signs of respiratory complications, including but not limited to: 1. Atelectesis 2. Hypoxia 3. Respiratory distress/failure 4. Pneumonia 5. Pneumothrax
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rocuronium | Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex |
| DRUG | Cisatracurium | Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine |
| DRUG | Sugammadex | Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex |
| DRUG | Neostigmine | Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine |
Timeline
- Start date
- 2025-08-26
- Primary completion
- 2026-12-31
- Completion
- 2027-08-26
- First posted
- 2025-10-02
- Last updated
- 2026-02-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07203287. Inclusion in this directory is not an endorsement.